Tagged with AI

Aipm ukraine What was the market need that spawned the creation of AIPM in 2009 considering that there were already other trade associations in Ukraine that were representing the interests of international pharmaceutical companies? What was the vision for this association? The idea of establishing AIPM originated much before 2009 and it…

BIOTEC Thailand As one of the figureheads of the BIOTECh industry in Thailand, could you introduce your background to our readers? I was trained as a biochemist in Thailand, and did my Master’s Degree and PhD in the US at the University of Connecticut. I did two post-Doctorates, one at Rutgers University…

Roche Ukraine As a leader responsible for heading Roche’s operations since its establishment of an LLC in Ukraine in 2009, what do you consider have been the main achievements of the company? The last two years have been very important and active for the development of Roche in Ukraine, particularly since we…

Nobel Pharma Ukraine Nobel Pharma has quite a history in the CIS region as this region is becoming increasingly important for the company. What is the company’s story in Ukraine? Nobel Pharma Ukraine has been established 6 years ago, we have finished 5 years of active marketing in Ukraine. First let me provide…

Teva Ukraine Since 2006 Teva has been on a solid phase of growth and consolidation, mainly through the acquisitions of IVAX in 2006, Pliva (Barr) in 2008 and ratiopharm in 2010, which have transformed the company from the number 40 global pharmaceutical player to a top-10 pharma company today. As the person…

Nycomed Ukraine Following Takeda’s acquisition of Nycomed earlier this year, how has the transaction affected your operations in Ukraine and what synergies were generated by it? Regarding the integration process, we are adapting our corporate cultures as quickly as possible. Luckily, I found out that both our cultures are very similar. It…

Eisai Europe As the head of Eisai’s European operations, how would you assess the relevance of the European market for Eisai’s global operations when compared to the US or emerging markets? Gary Hendler (GH): Eisai are currently present in 17 European markets as Eisai and several others via distributors. However it is…

Array As a Taiwanese national and Country Head of Novartis Taiwan, what is your opinion on the current state of the pharmaceutical industry in Taiwan, and what are your hopes for the future? I am of the opinion that it is going to get worse before it gets better. The National…

Hospira Taiwan What is exciting about the Taiwanese market for Hospira today? Hospira is a US-based company, which used to be part of Abbott Laboratories. A major part of the portfolio for the company is devices, which is mainly driven by its Medication Management Systems (MMS) portfolio. The rest of the company’s…

Daiichi Sankyo Germany DAIICHI SANKYO in Germany, Austria and Switzerland DAIICHI SANKYO wants to be a Global Pharma Innovator with Germany at the center of this process on the European continent. An example of this development is your manufacturing facility in Pfaffenhofen, a basis to export to more than 50 countries. Can you…

Association of Innovative Pharmaceutical Manufacturers (AIPM) Hungary - Innovatív Gyógyszergyártók Egyesülete With various new government measures, the pharmaceutical and healthcare sector in Hungary has been undergoing quite a turbulent period recently. But if we first take a step back… Can you explain to our readers what has attracted most of your members to have a presence in the Hungarian market? V.N.I.:…

Daiichi Sankyo Nederland “Two traditions one vision” was the phrase used to describe the 2005 merger that formed Daiichi Sankyo as it is today. While referring specifically to a corporate merger, its message of marrying two different cultures can be applied to the process of managing the Benelux region given the different market…